DUSP1 and glioblastoma: These data provide further evidence for the development of HDACIs as potential therapeutics against this type of cancer, particularly in combination with TMZ and using MKP1 as a biomarker and a strong rationale for the development of novel strategies targeting MKP1 for glioblastoma.